Acadia Pharmaceuticals
ACAD
188 hedge funds and large institutions have $4.12B invested in Acadia Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 67 increasing their positions, 67 reducing their positions, and 30 closing their positions.
30% more capital invested
Capital invested by funds: $3.17B → $4.12B (+$946M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more call options, than puts
Call options by funds: $36.7M | Put options by funds: $32.2M
0% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 67
3% less funds holding
Funds holding: 193 → 188 (-5)
17% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$33.3M |
| 2 |
VAM
Visium Asset Management
New York
|
+$32.4M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
+$27.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$22.6M |
| 5 |
Millennium Management
New York
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$34.8M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$17.9M |
| 3 |
CCI
Columbus Circle Investors
|
-$17.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.4M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$14.9M |
ACAD Hedge Fund Activity: Q2 2015 in Review
188 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2015, worth a combined $4.12B — up 30% from $3.17B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ACAD and 25 opened new positions — a net loss of 5 holders — while 67 trimmed existing stakes and 67 added.
The largest buyer was Invesco, adding an estimated $33.3M. The largest seller was Point72 Asset Management, cutting an estimated $34.8M.
- 188 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2015, down from 193 in Q1 2015.
- Funds reported $4.12B of Acadia Pharmaceuticals stock for Q2 2015, up 30% quarter-over-quarter.
- 25 funds opened new Acadia Pharmaceuticals positions in Q2 2015 and 30 closed out, a net change of -5 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2015 was Invesco, an estimated $33.3M added.
- The largest Acadia Pharmaceuticals seller in Q2 2015 was Point72 Asset Management, an estimated $34.8M sold.
Based on aggregated 13F filings for Q2 2015.